Parametrica Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Parametrica Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-37,387	Closed	-$87K	–	330
2022 Q1	$87K	Buy	+37,387	New	+$117K	0.06%	227
2021 Q4	–	Sell	-11,058	Closed	-$84K	–	91
2021 Q3	$84K	Buy	+11,058	New	+$93.8K	0.06%	72

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Parametrica Management's SRNE Position: Q2 2022 in Review

Parametrica Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2022, closing a stake of 37,387 shares — an estimated $87K sold.

Parametrica Management first reported a position in SRNE in Q3 2021 and held it in 2 quarters. The position peaked at $87K in Q1 2022. 229 funds tracked by Wall St. Rank hold SRNE as of Q2 2022.

Parametrica Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
Parametrica Management sold 37,387 Sorrento Therapeutics, Inc. shares in Q2 2022, an estimated $87K.
Parametrica Management first reported a position in Sorrento Therapeutics, Inc. in Q3 2021 and held it in 2 quarters.
Parametrica Management's Sorrento Therapeutics, Inc. position peaked at $87K in Q1 2022.
229 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2022.

Based on Parametrica Management's 13F filing for Q2 2022, filed 22 Jul 2022.